Patients in receipt of a drug that slows the progression of genetic emphysema do not know when they will receive their next dose because of confusion over who is to administer the drug.

Patients set to lose access to a drug the State has refused to reimburse have been granted a six-month reprieve as the manufacturer says it will continue to supply it free of charge.